Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

MicroPort®
微创心通

MicroPort CardioFlow Medtech Corporation
微创心通医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2160)

(1) POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 4, 2026; (2) RETIREMENT OF NON-EXECUTIVE DIRECTOR; AND (3) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE BOARD COMMITTEE

Reference is made to the circular dated May 12, 2026 (the "**Circular**") incorporating, amongst others, the notice dated May 12, 2026 (the "**AGM Notice**") of the annual general meeting (the "**AGM**") of MicroPort CardioFlow Medtech Corporation (the "**Company**" together with its subsidiaries, the "**Group**"). Unless otherwise stated, capitalised terms used herein shall have the same meanings as those defined in the Circular and AGM Notice.

The board (the "**Board**") of directors (the "**Director(s)**") of the Company is pleased to announce that at the AGM held on June 4, 2026, all proposed resolutions as set out in the AGM Notice were duly approved by the Shareholders by way of poll.

(1) POLL RESULTS OF ANNUAL GENERAL MEETING HELD ON JUNE 4, 2026

As at the date of the AGM, the total number of issued shares of the Company was 1,273,311,439 shares. There was no treasury Shares held by the Company (including any treasury Shares held or deposited with the Central Clearing and Settlement System established and operated by Hong Kong Securities Clearing Company Limited) and as such no voting rights of treasury Shares have been exercised at the AGM. No Shareholders were required under the Listing Rules to abstain from voting on any of the resolutions at the AGM and no Shareholders were entitled to attend and abstain from voting in favor as set out in Rule 13.40 of the Listing Rules. No Shareholders have stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the AGM.

The Company's share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

All the Directors, namely Mr. Zhang Ruinian and Mr. Philippe Wanstok as the executive Directors, Mr. Chen Guoming, Dr. Brian Chang, Mr. Deng Aoyi and Ms. Wu Xia as the non-executive Directors, and Mr. Jonathan H. Chou, Ms. Sun Zhixiang and Dr. Hu Bingshan as the independent non-executive Directors attended the AGM either in person or by electronic means.

The poll results in respect of each resolution proposed at the AGM were as follow:

ORDINARY RESOLUTIONS		**Number of Votes (%)**	
		For	**Against**
1.	To consider and receive the audited consolidated financial statements of the Company and the reports of the Directors and the auditors of the Company for the year ended December 31, 2025	690,051,302 98.104019%	13,336,093 1.895981%
2.	To grant a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company (excluding treasury shares)	690,051,302 98.104019%	13,336,093 1.895981%
3.	To grant a general mandate to the Directors to allot, issue and deal with additional shares of the Company not exceeding 20% of the total number of issued shares of the Company (excluding treasury shares)	689,276,248 97.993830%	14,111,147 2.006170%
4.	To extend the general mandate granted to the Directors to issue shares of the Company by adding thereto the shares to be bought back by the Company	689,276,248 97.993830%	14,111,147 2.006170%

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	Against
5.	(i) To re-elect Dr. Brian Chang as a non-executive Director	690,051,302 98.104019%	13,336,093 1.895981%
	(ii) To re-elect Mr. Philippe Wanstok as an executive Director	690,051,302 98.104019%	13,336,093 1.895981%
	(iii) To re-elect Mr. Deng Aoyi as a non-executive Director	690,047,128 98.103425%	13,340,267 1.896575%
	(iv) To re-elect Dr. Hu Bingshan as an independent non-executive Director	690,047,124 98.103425%	13,340,271 1.896575%
	(v) To re-elect Mr. Jonathan H. Chou as an independent non-executive Director	690,051,302 98.104019%	13,336,093 1.895981%
6.	To authorise the Board to fix the remuneration of the Directors	690,051,302 98.104019%	13,336,093 1.895981%
7.	To re-appoint KPMG as the auditors of the Company and authorize the Board to fix their remuneration	689,942,502 98.088551%	13,444,893 1.911449%

Note: The full text of the above resolutions are set out in the AGM Notice.

As more than 50% of votes were cast in favour of the ordinary resolutions nos. 1 to 7 above, all such resolutions were duly passed by the Shareholders as ordinary resolutions.

(2) RETIREMENT OF NON-EXECUTIVE DIRECTOR

Ms. Wu Xia ("**Ms. Wu**") retired as a non-executive Director with effect from the conclusion of the AGM and did not offer herself for re-election at the AGM as disclosed in the Circular. Accordingly, Ms. Wu ceased to act as a member of the commercialization committee (the "**Commercialization Committee**") of the Company with effect from the conclusion of the AGM.

Ms. Wu has confirmed that she has no disagreement with the Board and there is no matter relating to her retirement that needs to be brought to the attention of the Shareholders or the Stock Exchange.

The Board would like to take this opportunity to express its appreciation to Ms. Wu for her valuable contributions to the Company during her tenure of office with the Board and the Company.

(3) APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE BOARD COMMITTEE

The Board is also pleased to announce that Mr. Mao Junxiang (茅駿翔) ("**Mr. Mao**") has been appointed as an independent non-executive Director and a member of the Commercialization Committee, with effect from June 4, 2026. The biographical details of Mr. Mao are set out below:

Mr. Mao, aged 54, has more than 30 years of experiences in banking and finance. Mr. Mao worked in multiple banks from 1996 to 2010, including Citibank (China) Co., Ltd. Shanghai Branch (花旗銀行(中國)有限公司上海分行) from December 1996 to March 2005, Societe Generale Asia Limited from April 2005 to May 2007, the Deutsche Bank AG, Hong Kong Branch from May 2007 to July 2009, and Zhong De Securities Co., Ltd. (中德證券有限責任公司) from August 2009 to July 2010. He worked at Citigroup Global Markets Asia Limited as the managing director of Hong Kong Capital Markets Coverage, from July 2010 to July 2024. He has been serving as an independent director of China Life Insurance (Overseas) Company Limited since February 2025, and a panel member of the Mandatory Provident Fund Schemes Appeal Board of Hong Kong since October 2025. In addition, he has been serving as a director of Guangzhou EHolly Intelligent Equipment Co., Ltd. (廣州市易鴻智能裝備股份有限公司) since April 2026.

Mr. Mao obtained the dual bachelor's degrees in management information systems and technology English from Tianjian University (天津大學) in the PRC in July 1993. He obtained a master's degree in business administration from Fudan University (復旦大學) in the PRC in January 2003.

Mr. Mao has entered into a letter of appointment with the Company. The initial term of his appointment letter shall commence from the effective date of his appointment for a period of three years, and shall be subject to re-election as and when required under the articles of association of the Company and the Listing Rules, until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than three months' prior notice in writing. Pursuant to his letter of appointment, he is entitled to an annual director's fee of RMB200,000. Mr. Mao's remuneration will be subject to annual review by the remuneration committee of the Company and the Board from time to time with reference to the Company's remuneration policy, the prevailing market level and his responsibilities and performance.

Mr. Mao shall only hold office until the next annual general meeting of the Company and will be eligible for and subject to re-election at such meeting in accordance with the articles of association of the Company.

Mr. Mao confirms that save as disclosed above, as of the date of this announcement, he does not (i) hold any other position in the Company or its subsidiaries nor any directorship in public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years; (ii) have any other major appointments and professional qualifications; (iii) have any relationship with any Directors, senior management, substantial or controlling shareholders (as defined under the Listing Rules) of the Company; and (iv) have, and is not deemed to have, any interests or short positions in any shares, underlying shares or debentures (within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong)) of the Company or its associated corporations.

Mr. Mao has confirmed that he meets the independence criteria as set out in Rule 3.13 of the Listing Rules.

Save as disclosed above, the Board is not aware of any other information which is discloseable pursuant to any of the requirements under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules, and there is no other matter relating to the appointment of Mr. Mao that need to be brought to the attention of the Shareholders.

The Board would like to welcome Mr. Mao for joining as a member of the Board.

By Order of the Board
MicroPort CardioFlow Medtech Corporation
Chen Guoming
Chairman

Hong Kong, June 4, 2026

As of the date of this announcement, the executive Directors are Mr. Zhang Ruinian and Mr. Philippe Wanstok, the non-executive Directors are Mr. Chen Guoming, Dr. Brian Chang and Mr. Deng Aoyi, and the independent non-executive Directors are Mr. Jonathan H. Chou, Ms. Sun Zhixiang, Dr. Hu Bingshan and Mr. Mao Junxiang.